Last viewed:
adct
Prices are updated after-hours
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
(0.0% 1d)
(0.6% 1m)
(113.5% 1y)
(0.0% 2d)
(0.0% 3d)
(8.9% 7d)
(16.93%
volume)
Earnings Calendar:
Market Cap: $ 390,882,080
http://www.adctherapeutics.com
Sec
Filling
|
Patents
| 127 employees
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
antibody
add to watch list
Paper trade
email alert is off
Press-releases
Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs
Published: 2024-04-08
(Crawled : 15:00)
- biospace.com/
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| -4.8%
| O: 0.4%
H: 7.17%
C: 1.39%
merck
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2024-04-04
(Crawled : 11:00)
- globenewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| 7.94%
| O: 0.68%
H: 11.71%
C: 6.08%
zynlonta
trial
therapeutics
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
Published: 2024-04-03
(Crawled : 11:00)
- globenewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| 10.44%
| O: 2.32%
H: 0.0%
C: 0.0%
research
therapeutics
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Published: 2024-04-01
(Crawled : 20:00)
- globenewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| 7.21%
| O: 0.0%
H: 0.0%
C: -2.93%
grants
therapeutics
Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2.06 billion between 2022 and 2027, Technavio
Published: 2024-03-26
(Crawled : 04:00)
- prnewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| 13.33%
| O: 0.0%
H: 8.1%
C: 3.57%
therapeutics
market
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Published: 2024-03-13
(Crawled : 11:00)
- globenewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| 6.97%
| O: -3.82%
H: 2.57%
C: -8.88%
business
year
therapeutics
financial
results
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
Published: 2024-03-06
(Crawled : 12:30)
- globenewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| -1.24%
| O: -0.21%
H: 5.61%
C: 3.95%
therapeutics
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
Published: 2024-03-06
(Crawled : 12:00)
- globenewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| -1.24%
| O: -0.21%
H: 5.61%
C: 3.95%
conference
therapeutics
financial
results
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05
(Crawled : 23:00)
- globenewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| -1.24%
| O: -0.21%
H: 5.61%
C: 3.95%
association
presentation
cancer
research
meeting
therapeutics
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-27
(Crawled : 12:00)
- globenewswire.com
ADCT
|
$4.72
-0.84%
0.0%
320K
|
Health Technology
| -7.39%
| O: 3.5%
H: 0.0%
C: -5.83%
conference
health
care
therapeutics
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount